// App-Quantinova.ai

P554 : Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study

Researchers

Presenter

  • Lim, S

Principal Investigators

  • Lehmann, A

  • Lindsay, J

  • Gaya, D

  • Caulfield, L

  • Dhar, A

  • Ritchie, S

  • Limdi, J

  • Taylor, J

  • Raine, T

  • Balendran, K

  • Shuttleworth, E

  • Kwok, J

  • Cococcia, S

  • Murray, C

  • Walker, G

  • Aldridge, R

  • George, B

  • Colbert, R

  • Dawson, P

  • Jameson, E

  • Irving, P

  • Sharma, E

  • Lees, C

  • Samaa, M

Medical Centers

  • Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom

  • Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom

  • Royal London Hospital, Gastroenterology, London, United Kingdom

  • NHS Greater Glasgow and Clyde, Microbiology, Glasgow, United Kingdom

  • County Durham and Darlington NHS Foundation Trust, Durham, United Kingdom

  • Pennine Acute Trust, Gastroenterology, Manchester, United Kingdom

  • Cambridge University Hospitals, Gastroenterology, Cambridge, United Kingdom

  • Lancashire Teaching Hospital, Gastroenterology, Preston, United Kingdom

  • Royal London Hospital, Gastroenterology, London, United Kingdom

  • Torbay Hospital, Gastroenterology, Torbay, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved